Tag: Tarsus pharmaceuticals

An estimated 25 million eye care patients in the U.S. are affected by Demodex blepharitis. In response to this widespread condition, the FDA approved Xdemvy on July 24, 2023. So, to answer the question of **how long has Xdemvy been on the market?**, as of September 2025, it has been available for over two years.

Without insurance, the list price for a 6-week treatment of Xdemvy can exceed $2,000, but most commercially insured patients pay significantly less through manufacturer savings programs. This guide explains how much does Xdemvy cost and how to access available financial assistance to make it affordable.